Therapeutic Approach | Drug Combination | Administration Sequence | Synergy | Adverse Effects | References |
---|---|---|---|---|---|
Immune Checkpoint Inhibitor + Nanoparticle Drug Delivery System | Anti-PD-1 antibody + Paclitaxel-loaded polymeric nanoparticles | Simultaneous | Synergistic | Immune-related adverse events (irAEs) such as rash, fatigue, diarrhea | [215] |
Oncolytic Virus + Nanoparticle Drug Delivery System | T-VEC + Docetaxel-loaded liposomal nanoparticles | Sequential | Synergistic | Influenza-like symptoms, mild rash | [215] |
Adoptive Cell Therapy + Nanoparticle Drug Delivery System | CAR-T cells + siRNA-loaded nanoparticles | Simultaneous | Synergistic | Cytokine release syndrome, neurotoxicity | [214] |
Immune Stimulator + Nanoparticle Drug Delivery System | CpG-ODN + Doxorubicin-loaded liposomal nanoparticles | Sequential | Synergistic | Flu-like symptoms, injection site reactions | [269] |
Nanoparticle Drug Delivery System + Cytokine Therapy | IL-2-loaded nanoparticles + Doxorubicin-loaded liposomes | Simultaneous | Synergistic | Fever, chills, hypotension | [271] |
Immune Checkpoint Inhibitor + Nanoparticle Drug Delivery System | Anti-CTLA-4 antibody + Sirolimus-loaded polymeric nanoparticles | Sequential | Synergistic | Diarrhea, rash, colitis | [241] |
Oncolytic Virus + Nanoparticle Drug Delivery System | Adenovirus + Docetaxel-loaded lipid nanoparticles | Simultaneous | Synergistic | Fatigue, fever, nausea | [215] |
Adoptive Cell Therapy + Nanoparticle Drug Delivery System | TILs + Paclitaxel-loaded dendrimers | Simultaneous | Synergistic | Cytokine release syndrome, neurotoxicity | [215] |
Immune Stimulator + Nanoparticle Drug Delivery System | CpG-ODN + Curcumin-loaded polymeric nanoparticles | Sequential | Synergistic | Injection site reactions, mild gastrointestinal symptoms | [269] |
Nanoparticle Drug Delivery System + TLR Agonist | Imiquimod-loaded nanoparticles + Gemcitabine | Simultaneous | Synergistic | Injection site reactions, flu-like symptoms | [43] |
Immune Checkpoint Inhibitor + Nanoparticle Drug Delivery System | Anti-PD-1 antibody + Docetaxel-loaded nanocrystals | Sequential | Synergistic | Fatigue, neutropenia, anemia | [15] |
Oncolytic Virus + Nanoparticle Drug Delivery System | Measles virus + Paclitaxel-loaded liposomes | Simultaneous | Synergistic | Injection site reactions, fever, fatigue | [215] |
Adoptive Cell Therapy + Nanoparticle Drug Delivery System | CAR-T cells + Nanogels loaded with anti-PD-1 antibody | Simultaneous | Synergistic | Cytokine release syndrome, hypotension | [214] |
Immune Stimulator + Nanoparticle Drug Delivery System | Poly(I:C) + Doxorubicin-loaded liposomes | Sequential | Synergistic | Flu-like symptoms, injection site reactions | [269] |
Nanoparticle Drug Delivery System + Cancer Vaccine | Polymeric nanoparticles loaded with tumor antigens + Adjuvant | Simultaneous | Synergistic | Injection site reactions, fever | [101] |
Immune Checkpoint Inhibitor + Nanoparticle Drug Delivery System | Anti-PD-L1 antibody + Paclitaxel-loaded nanofibers | Sequential | Synergistic | Nausea, fatigue, neuropathy | [215] |
Nanoparticle Drug Delivery System + Chemotherapy | Oxaliplatin-loaded nanoparticles + 5-FU | Simultaneous | Synergistic | Peripheral neuropathy, diarrhea | |
Immune Checkpoint Inhibitor + Nanoparticle Drug Delivery System | Anti-CTLA-4 antibody + Paclitaxel-loaded micelles | Sequential | Synergistic | Diarrhea, fatigue, neutropenia | [272] |
Oncolytic Virus + Nanoparticle Drug Delivery System | Newcastle disease virus + Irinotecan-loaded liposomes | Simultaneous | Synergistic | Influenza-like symptoms, mild rash | |
Adoptive Cell Therapy + Nanoparticle Drug Delivery System | CAR-T cells + DOX-loaded gold nanoparticles | Simultaneous | Synergistic | Cytokine release syndrome, neurotoxicity | [214] |
Immune Stimulator + Nanoparticle Drug Delivery System | MPLA + Gemcitabine-loaded liposomes | Sequential | Synergistic | Injection site reactions, flu-like symptoms | [269] |
Nanoparticle Drug Delivery System + TLR Agonist | R848-loaded nanoparticles + Docetaxel | Simultaneous | Synergistic | Injection site reactions, myelosuppression | [43] |
Immune Checkpoint Inhibitor + Nanoparticle Drug Delivery System | Anti-PD-1 antibody + Doxorubicin-loaded carbon nanotubes | Sequential | Synergistic | Fatigue, neutropenia, anemia | [109] |
Oncolytic Virus + Nanoparticle Drug Delivery System | Reovirus + Cisplatin-loaded liposomes | Simultaneous | Synergistic | Injection site reactions, flu-like symptoms | [215] |
Adoptive Cell Therapy + Nanoparticle Drug Delivery System | TCR-T cells + Paclitaxel-loaded solid lipid nanoparticles | Simultaneous | Synergistic | Cytokine release syndrome, neurotoxicity | [215] |
Immune Stimulator + Nanoparticle Drug Delivery System | R848 + Gemcitabine-loaded dendrimers | Sequential | Synergistic | Injection site reactions, flu-like symptoms | [43] |
Nanoparticle Drug Delivery System + Cancer Vaccine | PLGA nanoparticles loaded with tumor antigen + CpG-ODN | Simultaneous | Synergistic | Injection site reactions, fever | [273] |
Immune Checkpoint Inhibitor + Nanoparticle Drug Delivery System | Anti-PD-L1 antibody + Paclitaxel-loaded nanocapsules | Sequential | Synergistic | Nausea, fatigue, neuropathy | [215] |